Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Arc-1 vs Midi Health

Arc-1
Graded #417

Lower grade

vs+0.10000000000000142
Midi Health
Graded #414

Higher grade

The verdict

Midi Health takes it — 56.4/100 to 56.3/100, but only just.

Midi Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Midi Health is a nationwide 50-state menopause and perimenopause telehealth platform. Arc-1 is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMidi Health +1
44
45
Dose & formulationArc-1 +14
54
40
Clinical oversightMidi Health +6
72
78
Labs & monitoringEven
52
52
FulfillmentMidi Health +16
62
78
Contract termsArc-1 +6
61
55
Arc-1 · left barMidi Health · right bar

The numbers

MetricArc-1Midi Health
WeighScore56.3/10056.4/100
GradeCC
Scorecard rank#417#414
Semaglutide$200/mo (0.5 mg dose, compounded)Not disclosed
Tirzepatide$200/mo (2.5 mg dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Arc-1

Graded #417 · C

Strengths

  • Both compounded semaglutide and tirzepatide available
  • Per-dose purchasing — no subscription or membership required
  • 25% off plus free shipping promotion
  • Broader longevity formulary (rapamycin, NAD+, sermorelin)
  • LegitScript Certified badge now displayed on product pages

Where it loses points

  • No legal entity name or address disclosed
  • State availability not disclosed
  • No named clinicians or pharmacy partners
  • Per-dose pricing still climbs with dose (semaglutide 2.5mg is $549.99/mo, tirzepatide 7.5mg $399.99/mo)
Midi Health

Graded #414 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard